Notably, the most frequently activated pathways in tissue after the treatment were immune-related ones along with the upregulation of HLA class I on melanoma cells and increased CD8+PD-1+ T cells and CD20+ B cells in posttreatment tumor cores. The gene discussed is CD8A; the disease is melanoma.